Together, these studies support the consideration of biomarker testing for tumor expression of CLDN18.2 and the use of zolbetuximab as a first-line therapy in combination with chemotherapy as a new potential standard of care in this biomarker-selected patient population. Here, CLDN18 is linked to neoplasm.